



**Vietnam**

**Country Operational Plan**

**FY 2015**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD				0	1,882,800
HHS/CDC	1,857,750	12,292,833		14,150,583	10,573,759
HHS/HRSA		58,750		58,750	0
HHS/SAMHSA		1,200,000		1,200,000	0
State		91,000		91,000	162,000
State/EAP				0	30,000
USAID		17,961,773		17,961,773	10,889,335
<b>Total</b>	<b>1,857,750</b>	<b>31,604,356</b>	<b>0</b>	<b>33,462,106</b>	<b>23,537,894</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	State/EAP	DOD	HHS/CDC	HHS/HRSA	HHS/SAMHSA	USAID		
HBHC			0	1,279,101		253,469	1,779,804	0	3,312,374
HKID				0				0	0
HLAB			0	1,795,968				0	1,795,968
HMBL			0					0	0
HMIN			0					0	0
HTXD							4,443,925	0	4,443,925
HTXS			0	4,570,477	58,750	1	3,507,431	0	8,136,659
HVCT			0	1,278,007			313,956	0	1,591,963
HVMS	91,000		0	218,044		357,753	2,088,459	0	2,755,256
HVOP		0	0	197,131			768,051	0	965,182
HVSI			0	1,392,771			748,874	0	2,141,645
HVTB			0	895,266			530,434	0	1,425,700
IDUP				796,236		588,777	1,882,555	0	3,267,568



MTCT			0	651,283				0	<b>651,283</b>
OHSS			0	654,793			1,870,372	0	<b>2,525,165</b>
PDCS				150,000				0	<b>150,000</b>
PDTX				271,506			27,912	0	<b>299,418</b>
	<b>91,000</b>	<b>0</b>	<b>0</b>	<b>14,150,583</b>	<b>58,750</b>	<b>1,200,000</b>	<b>17,961,773</b>	<b>0</b>	<b>33,462,106</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	2,806,852	0
HKID	0	0
HVTB	1,254,931	0
PDCS	150,000	0
<b>Total Technical Area Planned Funding:</b>	<b>4,211,783</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,513,694	0
HVSI	1,652,000	0
OHSS	2,373,659	0
<b>Total Technical Area Planned Funding:</b>	<b>5,539,353</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	0	0
HMIN	0	0
HVCT	1,500,000	0
HVOP	775,000	0
IDUP	2,852,423	0
MTCT	610,000	0
<b>Total Technical Area Planned Funding:</b>	<b>5,737,423</b>	<b>0</b>



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXD	4,429,969	0
HTXS	7,543,629	0
PDTX	271,506	0
<b>Total Technical Area Planned Funding:</b>	<b>12,245,104</b>	<b>0</b>

## Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	99 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	293,000	183,274
	Number of new ANC and L&D clients	295,000	188,095
	By: Known positives at entry	775	628
	By: Number of new positives identified	600	190
	Sum of Positives Status disaggregates	1,375	818
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		

	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		
	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	94 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,000	21,366

	Number of new ANC and L&D clients	93,000	21,366
	By: Known positives at entry	222	37
	By: Number of new positives identified	88	66
	Sum of Positives Status disaggregates	310	103
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator:		

	15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	90 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,235	786
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,375	839
	Life-long ART (including Option B+)	978	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	510	471
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	468	315

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	257	
	Single-dose nevirapine (with or without tail)		
	Sum of Regimen Type disaggregates	1,235	
	Sum of New and Current disaggregates	978	786
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	85 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	55	77
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	65	100

	Life-long ART (including Option B+)		
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy		48
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		29
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)		
	Single-dose nevirapine (with or without tail)		
	Sum of Regimen Type disaggregates		
	Sum of New and Current disaggregates		77
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	14,000	8,340
	Sex: Male	13,485	7,915
	Sex: Female	515	425

	Sum of Sex disaggregates	14,000	8,340
KP_MAT_TA	KP_MAT_TA Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months		8,200
	Sex: Female		422
	Sex: Male		7,778
	Sum of Sex Disaggregates		8,200
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.		50,000
	Total number of people in the target population		50,000
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		50,000
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: 10-14 Female		

	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/Sex disaggregates		50,000
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	85,241	92,696
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	26,030	17,137
	By key population type: Males who inject drugs (	37,028	50,724

	Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,173	2,707
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	21,010	15,024
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based		

	on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
KP_PREV_TA	KP_PREV_TA Percentage of	n/a	

	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)		
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,668	15,254
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	367	2,000
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,276	4,798

	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	25	2,000
	<p>By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	4,000	6,456
	<p>By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>		
	<p>By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)</p>		

	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	470,820	303,679
	By Test Result: Negative	460,533	294,713
	By Test Result: Positive	10,287	8,966
	Sum of Test Result disaggregates	470,820	303,679



	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		

	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	895	630
	Aggregated Age/sex - USE	111,090	96,682

	WITH HQ PERMISSION ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	475	653
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	358,360	203,509
	Sum of Aggregated Age/Sex <15	1,370	1,283
	Sum of Aggregated Age/Sex 15+	469,450	300,191
	Sum of Aggregated Age/Sex disaggregates	470,820	301,474
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		441
	Service Delivery Point by Result: Antenatal Clinic - Negative		144,054
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		1,283

	Service Delivery Point by Result: Under 5 Clinic - Positive		42
	Service Delivery Point by Result: Under 5 Clinic - Negative		1,241
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		700
	Service Delivery Point by Result: Tuberculosis - Positive		10
	Service Delivery Point by Result: Tuberculosis - Negative		690
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		500
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		10
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		490
	Service Delivery Point by Result: Outpatient		1,772

	Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		10
	Service Delivery Point by Result: Outpatient Department - Negative		1,762
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling		

	& Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		20
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		708
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		8,285
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		131,711
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by		

	Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		18,494
	Service Delivery Point by Result: Other - Positive		399
	Service Delivery Point by Result: Other - Negative		18,095
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	135,810	56,968
	By Test Result: Negative	133,847	55,241
	By Test Result: Positive	1,963	1,727
	Sum of Test Result disaggregates	135,810	56,968
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex:		



	Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex:		

	Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5	1
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,760	12,312
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5	2
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	119,040	32,761
	Sum of Aggregated Age/Sex <15	10	3
	Sum of Aggregated Age/Sex 15+	135,800	45,073
	Sum of Aggregated Age/Sex disaggregates	135,810	45,076
	Service Delivery Point by Result: Antenatal Clinic - All results		

	Service Delivery Point by Result: Antenatal Clinic - Positive		93
	Service Delivery Point by Result: Antenatal Clinic - Negative		23,320
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		3
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		3
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All		6,670

	results		
	Service Delivery Point by Result: Tuberculosis - Positive		331
	Service Delivery Point by Result: Tuberculosis - Negative		6,339
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		

	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		635

	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative		14,355
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		11,892
	Service Delivery Point by Result: Other - Positive		668
	Service Delivery Point by Result: Other - Negative		11,224
	Test Result by Aggregated Age and Sex: Negative <15 Male		
	Test Result by Aggregated Age and Sex: Negative 15+ Male		11,774
	Test Result by Aggregated Age and Sex: Negative <15 Female		2
	Test Result by Aggregated		32,240

	Age and Sex: Negative 15+ Female		
	Test Result by Aggregated Age and Sex: Positive <15 Male		
	Test Result by Aggregated Age and Sex: Positive 15+ Male		538
	Test Result by Aggregated Age and Sex: Positive <15 Female		
	Test Result by Aggregated Age and Sex: Positive 15+ Female		521
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		700
	Total number of registered new and relapsed TB cases, during the reporting period.		700
	Sex: Male		525
	Sex: Female		175
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age 15-19		
	Age: 20+		

	Status: Positive		20
	Status: Negative		680
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		6,670
	Total number of registered new and relapsed TB cases, during the reporting period.		6,670
	Age 15-19		
	Age: <1		
	Age: 1-4		
	Age: 10-14		
	Age: 20+		
	Age: 5-9		
	Sex: Female		3,335
	Sex: Male		3,335
	Status: Negative		6,339
	Status: Positive		331
	CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	71,480
Age/sex: <1 Male			
Age/sex: 1-4 Male			
Age/sex: 5-9 Male			

	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sun of Age/Sex disaggregates		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,110	1,735
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	44,140	36,506
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,970	1,685
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	23,260	20,659
	Sum of Aggregated Age/Sex disaggregates	71,480	60,585
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment	8,800	7,466

(WHO staging) OR CD4 count OR viral load		
Age/sex: <1 Male		
Age/sex: 1-4 Male		
Age/sex: 5-9 Male		
Age/sex: 10-14 Male		
Age/sex: 15-19 Male		
Age/sex: 20-24 Male		
Age/sex: 25-49 Male		
Age/sex: 50+ Male		
Age/sex: <1 Female		
Age/sex: 1-4 Female		
Age/sex: 5-9 Female		
Age/sex: 10-14 Female		
Age/sex: 15-19 Female		
Age/sex: 20-24 Female		
Age/sex: 25-49 Female		
Age/sex: 50+ Female		
Sum of Age/Sex disaggregates		
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	230	23
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,050	5,189
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	210	5
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,310	2,249
Sum of Aggregated Age/Sex	8,800	7,466

	disaggregates		
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	9,170	7,426
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/sex disaggregates		
	Aggregated Age/sex: <15 Male	250	178
	Aggregated Age/sex: 15+ Male	5,420	4,687
	Aggregated Age/sex: <15	240	166

	Female		
	Aggregated Age/sex: 15+ Female	3,260	2,395
	Sum of Aggregated Age/sex disaggregates	9,170	7,426
CARE_NEW_TA	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		1,839
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Aggregated Age/sex: <15 Female		5
	Aggregated Age/sex: <15		0

	Male		
	Aggregated Age/sex: 15+ Female		578
	Aggregated Age/sex: 15+ Male		1,256
	Sum of Aggregated Age/sex disaggregates	9,170	7,426
	Sum of age/sex disaggregates		
TB_IPT_DSD	TB_IPT_DSD Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		6,673
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		

	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		319
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		6,354
	Sex: Male		4,361
	Sex: Female		2,312
TB_IPT_TA	TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		1,655
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Age (Aggregated)- USE WITH HQ PERMISSION		5

	ONLY: <15		
	Age (Aggregated)- USE WITH HQ PERMISSION		1,650
	ONLY: 15+		
	Sex: Male		1,128
	Sex: Female		527
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	80 %	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,756	
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,195	
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male		
	Female		
	Sum of Sex disaggregates		
	Newly tested		
	Known HIV-positive		

	Sum of Test Status disaggregates		
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age disaggregates		
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		462
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		510
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		

	Sum of Age disaggregates		
	Aggregated Age: <15		
	Aggregated Age: 15+		462
	Sum of Aggregated Age disaggregates		462
	Male		227
	Female		235
	Sum of Sex disaggregates		462
	Known HIV-positive		
	Newly tested		
	Sum of Test Status disaggregates		
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	92 %	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	66,000	56,411
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4	71,480	60,585

	count OR viral load		
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		3,179
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		53,232
	Sum of Aggregated Age disaggregates		56,411
	Sex: Male		35,658
	Sex: Female		20,753
	Sum of Sex disaggregates		56,411
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		7,229
	Number of HIV positive adults and children who received at least one of the following during the reporting	8,800	7,466

	period: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		24
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		7,205
	Sum of Aggregated Age disaggregates		7,229
	Sex: Female		2,205
	Sex: Male		5,024
	Sum of Sex disaggregates		7,229
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	100 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,360	1,283
	Number of HIV- positive pregnant women identified during the reporting period	1,365	

	(include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth	1,080	
	By infants who received their first virologic HIV test between 2 and 12 months of age	280	
	Sum of Infant Age disaggregates	1,360	
	By infants with a positive virologic test result within 12 months of birth	90	
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		3
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a		

	virologic test within 2 months of birth		
	By infants who received their first virologic HIV test between 2 and 12 months of age		
	Sum of Infant Age disaggregates		
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
CARE_COMM_DSD	Number of HIV-infected adults and children receiving care and support services outside of the health facility		4,521
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		113
	Age/Sex: 15-19 Male		93
	Age/Sex: 20-24 Male		824
	Age/Sex: 25-49 Male		1,867
	Age/Sex: 50+ Male		69
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		69
Age/Sex: 15-19 Female		42	

	Age/Sex: 20-24 Female		287
	Age/Sex: 25-49 Female		1,129
	Age/Sex: 50+ Female		28
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	49,200	58,085
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Aggregated Age/Sex: <1 Male	13	36
	Aggregated Age/Sex: <1 Female	13	28
	Aggregated Age/Sex: 15+ Male	29,930	34,931
	Aggregated Age/Sex: 1-14 Female		1,557
	Aggregated Age/Sex: 15+ Female	15,350	19,895
	Sum of Aggregated Age/Sex <15	3,920	
	Sum of Aggregated Age/Sex 15+	45,280	54,826
	Sum of Aggregated Age/Sex disaggregates	49,200	54,826
	Aggregated Age/Sex: 1-14		1,638

	Male		
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	26	3,259
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,600	7,248
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Sum of Age/Sex disaggregations		
	Aggregated Age/Sex: <1 Male	5	2
	Aggregated Age/Sex: <1 Female	5	5
	Aggregated Age/Sex: 1-14 Male		255
	Aggregated Age/Sex: 15+ Male	4,200	17,928
	Aggregated Age/Sex: 1-14 Female		214
	Aggregated Age/Sex: 15+ Female	2,220	9,843
	Sum of Aggregated Age/Sex <15	180	
	Sum of Aggregated Age/Sex	6,420	27,771

	15+		
	Sum of Aggregated Age/Sex disaggregates	6,600	27,771
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	10	476
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,000	7,083
	By Age/Sex: <1 Male		
	By Age/Sex: 1-4 Male		
	By Age/Sex: 5-9 Male		
	By Age/Sex: 10-14 Male		
	By Age/Sex: 15-19 Male		
	By Age/Sex: 20-24 Male		
	By Age/Sex: 25-49 Male		
	By Age/Sex: 50+ Male		
	By Age/Sex: <1 Female		
	By Age/Sex: 1-4 Female		
	By Age/Sex: 5-9 Female		
	By Age/Sex: 10-14 Female		
	By Age/Sex: 15-19 Female		
	By Age/Sex: 20-24 Female		
	By Age/Sex: 25-49 Female		
	By Age/Sex: 50+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Grouping by Age: <1 Male	10	19
	Aggregated Grouping by Age/Sex: 1-14 Male		134
	Aggregated Grouping by Age/Sex: 15+ Male	4,347	4,304
	Aggregated Grouping by	10	18

	Age/Sex: <1 Female			
	Aggregated Grouping by Age/Sex: 15+ Female	2,257	2,489	
	Sum of Aggregated Age/Sex disaggregates	7,000	6,793	
	Pregnancy status		0	
	Breastfeeding status		0	
	Aggregated Grouping by Age/Sex: 1-14 Female		119	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)		1,781	
	By Age/Sex: <1 Male			
	By Age/Sex: 1-4 Male			
	By Age/Sex: 5-9 Male			
	By Age/Sex: 10-14 Male			
	By Age/Sex: 15-19 Male			
	By Age/Sex: 20-24 Male			
	By Age/Sex: 25-49 Male			
	By Age/Sex: 50+ Male			
	By Age/Sex: <1 Female			
	By Age/Sex: 1-4 Female			
	By Age/Sex: 5-9 Female			
	By Age/Sex: 10-14 Female			
	By Age/Sex: 15-19 Female			
	By Age/Sex: 20-24 Female			
	By Age/Sex: 25-49 Female			
	By Age/Sex: 50+ Female			
	Sum of Age/Sex disaggregates			
	Aggregated Grouping by Age: <1 Male			0
	Aggregated Grouping by			3

	Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male		1,219
	Aggregated Grouping by Age: <1 Female		0
	Aggregated Grouping by Age/Sex: 1-14 Female		5
	Aggregated Grouping by Age/Sex: 15+ Female		554
	Sum of Aggregated Age/Sex disaggregates		1,773
	Pregnancy status		
	Breastfeeding status		
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,454	5,521
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,328	6,431
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating		0

	ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating		0

	ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost		0

	to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning		0

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		0
	Denominator by Status: Breastfeeding		0
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		816
	Total number of adults and children who initiated ART in the 12 months prior to the		960

	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female		

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost		

	to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning		

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that	103	2

	are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		
LAB_ACC_TA	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		5
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1,627	20
	By clinical laboratories		20
	By Point-of-care testing sites		0
LAB_CAP_TA	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests		25
	By clinical laboratories		25
	By Point-of-care testing sites		0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and		

	successfully pass in an analyte-specific proficiency testing (PT) program		
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing		8
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		8
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		8
	CD4: Number of laboratories that perform this testing		4
	CD4: Number of laboratories that participate in this PT program		4
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		4
	Early infant diagnostics: Number of laboratories that perform this testing		0
	Early infant diagnostics: Number of laboratories that participate in this PT program		0
	Early infant diagnostics: Number of laboratories that		0

	achieve acceptable successful passing criteria in this PT program		
	HIV viral load: Number of laboratories that perform this testing		0
	HIV viral load: Number of laboratories that participate in this PT program		0
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		0
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		0
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate		0

	in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program		
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	CD4: Number of laboratories that participate in this PT program		0

	CD4: Number of laboratories that perform this testing		0
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	Early infant diagnostics: Number of laboratories that participate in this PT program		0
	Early infant diagnostics: Number of laboratories that perform this testing		0
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		0
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing		2
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	HIV viral load: Number of laboratories that participate		0

	in this PT program		
	HIV viral load: Number of laboratories that perform this testing		0
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		0
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		0
	TB diagnostics (Culture/DST): Number of laboratories that achieve		0

	acceptable successful passing criteria in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		0
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		24
	Number of viral load tests performed from adults and children on ART within the current reporting period		12
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		



	Age/Sex: 20+ Female		
	Pregnant		
	Breastfeeding		
	Test indication: Routine monitoring		
	Test indication: Targeted monitoring		

## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7345	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	4,429,969
9972	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	143,039
9974	Ho Chi Minh City Provincial AIDS Committee	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,200,000
9976	Ministry of Health, Vietnam	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,774,007
9977	National Institute for Hygiene and Epidemiology	Host Country Government Agency	U.S. Department of Health and Human Services/Centers	GHP-State	442,000

			for Disease Control and Prevention		
9998	Pasteur Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	410,000
10000	Harvard Medical School of AIDS Initiative in Vietnam	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,117,700
10118	Vietnam Administration for Medical Sciences	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	376,623
10831	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	170,616
10832	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	193,039

			Control and Prevention		
11609	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of East Asian and Pacific Affairs	GHP-State	0
12341	Vietnam Nurses' Association	Implementing Agency	U.S. Department of Defense	GHP-State	0
12736	Foundation for Innovative New Diagnostics	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	285,151
12909	U.S. Pharmacopeia	Implementing Agency	U.S. Agency for International Development	GHP-State	0
13007	Vietnam National TB Program	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	257,258
13147	TBD	TBD	Redacted	Redacted	Redacted
13234	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	502,522
13779	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	50,000

			Prevention		
13942	University of California at Los Angeles	University	U.S. Department of Health and Human Services/Substance Abuse and Mental Health Services Administration	GHP-State	350,000
14048	Hennepin Faculty Associates-Addiction Medicine Program	Private Contractor	U.S. Department of Health and Human Services/Substance Abuse and Mental Health Services Administration	GHP-State	150,000
14086	TBD	TBD	Redacted	Redacted	Redacted
14156	The Center for Community Health Research and Development	NGO	U.S. Agency for International Development	GHP-State	300,000
14159	FHI 360	NGO	U.S. Agency for International Development	GHP-State	5,196,444
14336	Hanoi Medical University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	277,000
16803	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	1,003,145

17369	Armed Forces Research Institute of Medical Sciences	Host Country Government Agency	U.S. Department of Defense	GHP-State	0
17370	Center for Community Health Promotion	NGO	U.S. Department of Defense	GHP-State	0
17371	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	1,700,000
17373	Institute of International Education	NGO	U.S. Agency for International Development	GHP-State	0
17374	Center for Community Health and Development	NGO	U.S. Agency for International Development	GHP-State	600,000
17375	The Center for Community Health Research and Development	NGO	U.S. Agency for International Development	GHP-State	500,000
17376	Center for Promotion of Quality of Life	NGO	U.S. Agency for International Development	GHP-State	400,000
17924	TBD	TBD	Redacted	Redacted	Redacted
17925	TBD	TBD	Redacted	Redacted	Redacted
17939	Management Systems International	Private Contractor	U.S. Agency for International Development	GHP-State	250,000
18149	Center for Community Health Promotion	NGO	U.S. Department of Defense	GHP-State	0



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7345</b>	<b>Mechanism Name: SCMS</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,429,969</b>	
<b>Applied Pipeline Amount: 7,000,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,429,969

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>7345</b>
<b>Mechanism Name:</b>	<b>SCMS</b>
<b>Prime Partner Name:</b>	<b>Partnership for Supply Chain Management</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	4,429,969	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 9972</b>	<b>Mechanism Name: APHL LAB</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 143,039</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	143,039

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 9972			
<b>Mechanism Name:</b> APHL LAB			
<b>Prime Partner Name:</b> Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	143,039	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	17		Redacted
LAB_CAP_DSD	By clinical laboratories	17		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	17		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	17		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	17		Redacted

## Implementing Mechanism Details



<b>Mechanism ID: 9974</b>	<b>Mechanism Name: HCMC PAC</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ho Chi Minh City Provincial AIDS Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 2,200,000</b>	
<b>Applied Pipeline Amount: 1,017,861</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,200,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1
Key Populations: FSW	1
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs



Key Populations: MSM and TG	1
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Education	1
Condom procurement	1

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 9974			
<b>Mechanism Name:</b> HCMC PAC			
<b>Prime Partner Name:</b> Ho Chi Minh City Provincial AIDS Committee			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	175,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	105,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	110,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,050,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	90,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	610	553	Redacted
PMTCT_ARV_DS	Number of HIV- positive pregnant	640	594	Redacted

D	women identified in the reporting period (including known HIV-positive at entry)			
PMTCT_ARV_DS D	Life-long ART (including Option B+)	610		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	450	331	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	160	222	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	610		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	610	553	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	80,000	124,700	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	82,000	124,700	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	480	451	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	160	143	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	640	594	Redacted

PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	65,000	7,100	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	71,000	7,100	Redacted
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	1,460	1,050	Redacted
KP_MAT_DSD	Sex: Male	1,250	996	Redacted
KP_MAT_DSD	Sex: Female	210	54	Redacted
KP_MAT_DSD	Sum of Sex disaggregates	1,460	1,050	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,448	11,886	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,630	5,191	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,400	5,264	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive	418	280	Redacted

	interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,000	1,152	Redacted
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,000		Redacted
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,000		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	101,580	86,886	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	380	293	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,080	7,420	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	200	293	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	85,920	78,880	Redacted

HTC_TST_DSD	Sum of Aggregated Age/Sex <15	580	586	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	101,000	86,300	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	101,580	86,886	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,800	15,803	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,360	3,188	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	68,440		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	68,440		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	8,360	15,803	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	76,800	15,803	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	17,805	12,864	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	710	673	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,863	7,768	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	670	650	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,562	3,773	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	17,805	12,864	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO	2,170		Redacted

	staging) OR CD4 count OR viral load			
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	90		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,320		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	80		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	680		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,170		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,570	1,038	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	60	62	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,000	655	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	60	30	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	450	291	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,570	1,038	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	1,570	1,038	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,105		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,300		Redacted

TB_ART_DSD	Newly tested	331		Redacted
TB_ART_DSD	Known HIV-positive	774		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,105		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	580	586	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	640		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	540		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	40		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	580		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	10		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,621	12,489	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	8	14	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	7	6	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	630		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	8,121	7,598	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	585		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,285	3,625	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,215		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	12,406	11,223	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	13,621	11,223	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	15	1,266	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	140		Redacted

TX_CURR_TA	Aggregated Age/Sex: <1 Male	3		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	2		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	80		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	0		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	60		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	0		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	140		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	0		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	140		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	5		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,925	958	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	8	14	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	60		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,137	574	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	7	4	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	50		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	678	292	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,925	866	Redacted
TX_NEW_DSD	Pregnancy status	200		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	139		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are	1,554		Redacted

	still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	153		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,850		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	160		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	200		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	21	12	Redacted
LAB_CAP_DSD	By clinical laboratories	21	12	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	21		Redacted
LAB_CAP_DSD	Sum of Site Support Type	21		Redacted

	disaggregates			
LAB_CAP_TA	Sum of Site Support Type disaggregates	21		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	17,537	12,608	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	17,805	12,864	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,373	1,295	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	16,164	11,313	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	17,537	12,608	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,170		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 9976</b>	<b>Mechanism Name: Vietnam Administration for HIV/AIDS Control (VAAC)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Vietnam	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 5,774,007</b>	
<b>Applied Pipeline Amount: 2,415,332</b>	



Funding Source	Funding Amount
GHP-State	5,774,007

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1
Key Populations: MSM and TG	1
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	1
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs

**Key Issues**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 9976			
<b>Mechanism Name:</b> Vietnam Administration for HIV/AIDS Control (VAAC)			
<b>Prime Partner Name:</b> Ministry of Health, Vietnam			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	130,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	IDUP	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	500,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,800,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	94,007	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	625	233	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	725	245	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	368		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	60	140	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	308	93	Redacted
PMTCT_ARV_DS	Maternal AZT (prophylaxis component)	257		Redacted

D	of WHO Option A during pregnancy and delivery)			
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	625		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	368	233	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	20	46	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	45	62	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	213,000	58,574	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	213,000	63,395	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	295	177	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	440	47	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	735	224	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	22,000	14,266	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	22,000	14,266	Redacted
PMTCT_STAT_TA	By: Known positives at entry	20	12	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	45	50	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	65	62	Redacted

KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	5,870	5,300	Redacted
KP_MAT_DSD	Sex: Male	5,635	5,030	Redacted
KP_MAT_DSD	Sex: Female	235	270	Redacted
KP_MAT_DSD	Sum of Sex disaggregates	5,870	5,300	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	19,703	32,750	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,933	23,675	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,970	1,262	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,800	462	Redacted
KP_PREV_TA	Number of key populations reached	1,068		Redacted

	with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required			
KP_PREV_TA	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	801		Redacted
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	267		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	288,790	142,590	Redacted
HTC_TST_DSD	By Test Result: Negative	283,821	138,243	Redacted
HTC_TST_DSD	By Test Result: Positive	4,969	4,347	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	288,790	142,590	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	515	299	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	52,500	44,321	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	275	314	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	235,500	97,656	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	790	613	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	288,000	141,977	Redacted

HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	288,790	142,590	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	34,010	28,990	Redacted
HTC_TST_TA	By Test Result: Negative	33,242	28,305	Redacted
HTC_TST_TA	By Test Result: Positive	768	685	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	34,010	28,990	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,400	8,984	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,600	20,006	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	10		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	34,000	28,990	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	34,010	28,990	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,655	26,284	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,020	846	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,276	15,188	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	960	800	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,399	9,450	Redacted
CARE_CURR_DS	Sum of Aggregated Age/Sex	30,655	26,284	Redacted

D	disaggregates			
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	3,096	3,340	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	160	96	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,233	2,064	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	154	64	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,549	1,116	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	3,096	3,340	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	3,096	3,340	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	616		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	875		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	780	613	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	735		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	22,470	25,002	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0	18	Redacted

TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0	20	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,130		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,800	14,338	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	970		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	6,570	9,105	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,100		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	20,370	23,443	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	22,470	23,443	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0	1,559	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,340	3,211	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	5	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	120		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,950	1,904	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	14	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	120		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,150	1,169	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,340	3,073	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,470	2,443	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	3,775	2,873	Redacted

	those lost to follow-up			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	255		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,215		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	275		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,500		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	28		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	28		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	28		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	28		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing	97		Redacted



	facilities with capacity to perform clinical laboratory tests			
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	97		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	97		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	97		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	27,900	23,667	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,655	26,284	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 9977</b>	<b>Mechanism Name: NIHE</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Institute for Hygiene and Epidemiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 442,000</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	442,000

### Sub Partner Name(s)



(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 9977			
<b>Mechanism Name:</b> NIHE			
<b>Prime Partner Name:</b> National Institute for Hygiene and Epidemiology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	217,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	225,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	600		Redacted
LAB_CAP_DSD	By clinical laboratories	600		Redacted



LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	600		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	600		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	600		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 9998</b>		<b>Mechanism Name: PI</b>	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Pasteur Institute			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: Yes		Managing Agency: HHS/CDC	

<b>Total All Funding Sources: 410,000</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	410,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1
----------------------------	---



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 9998			
<b>Mechanism Name:</b> PI			
<b>Prime Partner Name:</b> Pasteur Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	160,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	10		Redacted
LAB_ACC_DSD	By site support type: Direct Service	0		Redacted



	Delivery (DSD)			
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	10		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	10		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	10		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	501		Redacted
LAB_CAP_DSD	By clinical laboratories	1		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	500		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	501		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	501		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 10000</b>	<b>Mechanism Name: HAIVN</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Harvard Medical School of AIDS Initiative in Vietnam	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,117,700</b>	
<b>Applied Pipeline Amount: 241,341</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,117,700



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1
----------------------------	---

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10000		
<b>Mechanism Name:</b>	HAIVN		
<b>Prime Partner Name:</b>	Harvard Medical School of AIDS Initiative in Vietnam		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	268,659	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	761,542	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	87,499	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016	Planning Budget Targets
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	39,000	26,444	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,010	269	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	22,390	16,600	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	940	249	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	14,660	9,326	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	39,000	26,444	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	37,000	25,153	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0	2	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	0	5	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	960		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	23,090	15,737	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	890		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	12,060	8,941	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,850		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	35,150	24,678	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	37,000	24,678	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0	475	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of	39,000	26,444	Redacted



	the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
--	---	--	--	--

### Implementing Mechanism Details

<b>Mechanism ID: 10118</b>	<b>Mechanism Name: Department of Medical Administration</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Vietnam Administration for Medical Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 376,623</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	376,623

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1
----------------------------	---

### Key Issues

(No data provided.)

### Budget Code Information



<b>Mechanism ID:</b> 10118			
<b>Mechanism Name:</b> Department of Medical Administration			
<b>Prime Partner Name:</b> Vietnam Administration for Medical Sciences			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	40,215	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	86,408	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	30		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	30		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	30		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	30		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform	300		Redacted

	clinical laboratory tests			
LAB_CAP_DSD	By clinical laboratories	300		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	300		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	300		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	300		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 10831</b>	<b>Mechanism Name: CLSI LAB</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 170,616</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	170,616

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 10831			
<b>Mechanism Name:</b> CLSI LAB			
<b>Prime Partner Name:</b> Clinical and Laboratory Standards Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	170,616	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	12		Redacted
LAB_CAP_DSD	By clinical laboratories	12		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	12		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	12		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	12		Redacted



### Implementing Mechanism Details

<b>Mechanism ID: 10832</b>	<b>Mechanism Name: ASCP LAB</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 193,039</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	193,039

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 10832</b>			
<b>Mechanism Name: ASCP LAB</b>			
<b>Prime Partner Name: American Society of Clinical Pathology</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HLAB	193,039	0



Systems			
---------	--	--	--

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11609</b>	<b>Mechanism Name: Ambassador's Fund for HIV/AIDS Public Diplomacy</b>
Funding Agency: State/EAP	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 30,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 11609			
<b>Mechanism Name:</b> Ambassador's Fund for HIV/AIDS Public Diplomacy			
<b>Prime Partner Name:</b> U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 12341	<b>Mechanism Name:</b> VNA
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Vietnam Nurses' Association	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: DOD

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 400,000	
Funding Source	Funding Amount
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	12341		
<b>Mechanism Name:</b>	VNA		
<b>Prime Partner Name:</b>	Vietnam Nurses' Association		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 12736</b>	<b>Mechanism Name: FIND</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Innovative New Diagnostics	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 285,151</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	285,151



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 12736			
<b>Mechanism Name:</b> FIND			
<b>Prime Partner Name:</b> Foundation for Innovative New Diagnostics			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	285,151	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	45		Redacted
LAB_CAP_DSD	By clinical laboratories	45		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted



LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	45		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	45		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	45		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12909</b>	<b>Mechanism Name: PQM</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Pharmacopeia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	12909		
<b>Mechanism Name:</b>	PQM		
<b>Prime Partner Name:</b>	U.S. Pharmacopeia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13007</b>	<b>Mechanism Name: NTP</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Vietnam National TB Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 257,258</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	257,258

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13007			
<b>Mechanism Name:</b> NTP			
<b>Prime Partner Name:</b> Vietnam National TB Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	167,258	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	90,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	60		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	73		Redacted



	during the reporting period			
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	6		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	6		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	6		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13147</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 13234</b>	<b>Mechanism Name: Challenge TB</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 502,522</b>	
<b>Applied Pipeline Amount: 255,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	502,522

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1
----------------------------	---



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 13234			
<b>Mechanism Name:</b> Challenge TB			
<b>Prime Partner Name:</b> KNCV Tuberculosis Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	502,522	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	19	
LAB_CAP_DSD	By Point-of-care testing sites	19	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	19	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	19	
LAB_CAP_TA	Sum of Site Support Type disaggregates	19	

## Implementing Mechanism Details

<b>Mechanism ID:</b> 13779	<b>Mechanism Name:</b> WHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 50,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	50,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 13779</b>			
<b>Mechanism Name: WHO</b>			
<b>Prime Partner Name: World Health Organization</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 13942</b>	<b>Mechanism Name: Vietnam HIV-Addictions Technology Transfer Center (V-HATTC)</b>
Funding Agency: HHS/SAMHSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at Los Angeles	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 350,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	350,000

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

Human Resources for Health	350,000
----------------------------	---------

## Key Issues

(No data provided.)

## Budget Code Information



<b>Mechanism ID: 13942</b>			
<b>Mechanism Name: Vietnam HIV-Addictions Technology Transfer Center (V-HATTC)</b>			
<b>Prime Partner Name: University of California at Los Angeles</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	105,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	245,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14048</b>	<b>Mechanism Name: Methadone Clinical Support</b>
Funding Agency: HHS/SAMHSA	Procurement Type: Contract
Prime Partner Name: Hennepin Faculty Associates-Addiction Medicine Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
----------------------------	---------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 14048			
<b>Mechanism Name:</b> Methadone Clinical Support			
<b>Prime Partner Name:</b> Hennepin Faculty Associates-Addiction Medicine Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	104,999	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14086	<b>TBD:</b> Yes
<b>REDACTED</b>	



### Implementing Mechanism Details

<b>Mechanism ID: 14156</b>	<b>Mechanism Name: Strengthen In-Country Strategic Information Capacity for Sustainable HIV Response</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: The Center for Community Health Research and Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 300,000</b>	
<b>Applied Pipeline Amount: 200,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Key Populations: FSW	1
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	1
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners



Focus Area:	Monitoring and evaluation of MSM/TG programs
-------------	--

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14156		
<b>Mechanism Name:</b>	Strengthen In-Country Strategic Information Capacity for Sustainable HIV Response		
<b>Prime Partner Name:</b>	The Center for Community Health Research and Development		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	300,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14159</b>	<b>Mechanism Name: SMART TA</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,196,444</b>	
<b>Applied Pipeline Amount: 1,688,823</b>	



Funding Source	Funding Amount
GHP-State	5,196,444

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1
Key Populations: MSM and TG	1
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	1
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Food and Nutrition: Commodities	1

**Key Issues**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 14159			
<b>Mechanism Name:</b> SMART TA			
<b>Prime Partner Name:</b> FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	751,637	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	1,159,279	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,285,528	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	By: Known positives at entry	0	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0	

KP_MAT_DSD	Sex: Male	2,261	1,889
KP_MAT_DSD	Sex: Female	79	101
KP_MAT_DSD	Sum of Sex disaggregates	2,340	1,990
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	40,590	25,953
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13,950	4,919
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	15,590	7,929
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	340	426
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,710	10,660
HTC_TST_DSD	By Test Result: Negative	56,823	50,544
HTC_TST_DSD	By Test Result: Positive	3,627	3,254

HTC_TST_DSD	Sum of Test Result disaggregates	60,450	53,798
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,840	32,201
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	29,610	21,513
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	60,450	53,714
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	60,450	53,798
HTC_TST_TA	By Test Result: Negative	24,656	269
HTC_TST_TA	By Test Result: Positive	344	14
HTC_TST_TA	Sum of Test Result disaggregates	25,000	283
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,000	140
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,000	140
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	25,000	280
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	25,000	283
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	22,616	20,671
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	302	216
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,776	13,014
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	377	235
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,161	7,206
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	22,616	20,671
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	650	2,533

	OR viral load		
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8	5
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	414	1,814
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	217	714
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	650	2,533
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	4,461	2,917
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	3	20
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	3,183	1,875
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1	72
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,274	950
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	4,461	2,917
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	4,461	2,917
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	18	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	20	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	18,000	19,865
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	7	4
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	4	2

TX_CURR_DSD	Aggregated Age/Sex: <15 Male	292	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	11,408	12,485
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	315	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,985	6,946
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	607	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	17,393	19,431
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	18,000	19,431
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	11	434
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	450	2,458
TX_CURR_TA	Aggregated Age/Sex: <15 Male	8	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	292	1,750
TX_CURR_TA	Aggregated Age/Sex: <15 Female	8	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	142	707
TX_CURR_TA	Sum of Aggregated Age/Sex <15	16	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	434	2,457
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	450	2,457
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,300	2,803
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	3	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	23	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,511	1,747
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	23	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	743	996
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,300	2,743
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,250	1,818
TX_RET_DSD	Total number of adults and children who	2,500	2,105

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,250	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,500	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	20,155	19,370
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	22,616	20,671
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	650	2,533

### Implementing Mechanism Details

<b>Mechanism ID: 14336</b>	<b>Mechanism Name: HMU</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hanoi Medical University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 277,000</b>	
<b>Applied Pipeline Amount: 250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	277,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1
Key Populations: MSM and TG	1
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 14336</b>			
<b>Mechanism Name: HMU</b>			
<b>Prime Partner Name: Hanoi Medical University</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	217,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	60,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	4		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	4		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	4		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	4		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 16803</b>	<b>Mechanism Name: Healthy Markets</b>
----------------------------	--



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,003,145</b>	
<b>Applied Pipeline Amount: 695,512</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,003,145

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1
Key Populations: MSM and TG	1
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	1
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Condom programming	1



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 16803			
<b>Mechanism Name:</b> Healthy Markets			
<b>Prime Partner Name:</b> Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	95,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	208,145	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

## Implementing Mechanism Indicator Information



(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17369</b>	<b>Mechanism Name: AFRIMS</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Armed Forces Research Institute of Medical Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17369		
<b>Mechanism Name:</b>	AFRIMS		
<b>Prime Partner Name:</b>	Armed Forces Research Institute of Medical Sciences		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	2	2
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	2	
LAB_ACC_DSD	Sum of Support Type disaggregates	2	
LAB_ACC_TA	Sum of Support Type disaggregates	2	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	5	8
LAB_CAP_DSD	By clinical laboratories	5	8
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	5	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	5	
LAB_CAP_TA	Sum of Site Support Type disaggregates	5	

### Implementing Mechanism Details

<b>Mechanism ID: 17370</b>	<b>Mechanism Name: CHP</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Center for Community Health Promotion	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17370</b>			
<b>Mechanism Name: CHP</b>			
<b>Prime Partner Name: Center for Community Health Promotion</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	OHSS	0	0



Systems			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
PMTCT_STAT_DSD	By: Number of new positives identified	0	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,000	18,200
HTC_TST_DSD	By Test Result: Negative	19,810	18,140
HTC_TST_DSD	By Test Result: Positive	190	60
HTC_TST_DSD	Sum of Test Result disaggregates	20,000	18,200
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,980	12,740
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,020	5,460
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	20,000	18,200
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,000	18,200
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	400	766
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	300	536

CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	100	230
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	400	766
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	113	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	70	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	43	
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	113	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	45	131
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	30	93
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	15	38
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	45	131
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	45	131
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	320	729
TX_CURR_DSD	Age/Sex: 15+ Male	240	
TX_CURR_DSD	Age/Sex: 15+ Female	80	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	240	510
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	80	219
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	320	729
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	320	729
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	113	
TX_CURR_TA	Age/Sex: 15+ Male	70	

TX_CURR_TA	Age/Sex: 15+ Female	43	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	70	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	43	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	113	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	113	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	45	111
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	30	79
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	15	32
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	45	111
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	41	94
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	45	98
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	45	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of	45	

	the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	400	766
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	400	766
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	400	766
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	400	766
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	113	

### Implementing Mechanism Details

<b>Mechanism ID: 17371</b>	<b>Mechanism Name: Health Finance &amp; Governance (HFG)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,700,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,700,000



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17371			
<b>Mechanism Name:</b> Health Finance & Governance (HFG)			
<b>Prime Partner Name:</b> Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,700,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17373	<b>Mechanism Name:</b> CSO Capacity Building (PCD)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Institute of International Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17373</b>			
<b>Mechanism Name: CSO Capacity Building (PCD)</b>			
<b>Prime Partner Name: Institute of International Education</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**



<b>Mechanism ID: 17374</b>	<b>Mechanism Name: Community HIV Link-Northern Coast</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Community Health and Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 600,000</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	600,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	1
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	1
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 17374			
<b>Mechanism Name:</b> Community HIV Link-Northern Coast			
<b>Prime Partner Name:</b> Center for Community Health and Development			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	275,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	175,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,450	7,675

KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	80	539
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,200	5,102
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	70	273
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100	385
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	600	
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100	



KP_PREV_TA	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	475	
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	25	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,000	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	500	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,500	

### Implementing Mechanism Details

<b>Mechanism ID: 17375</b>	<b>Mechanism Name: Community HIV Link-Northern Mountains</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: The Center for Community Health Research and Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

### Sub Partner Name(s)

Custom



(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	1
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	1
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Condom programming	1

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17375			
<b>Mechanism Name:</b> Community HIV Link-Northern Mountains			
<b>Prime Partner Name:</b> The Center for Community Health Research and Development			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	275,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HVSI	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,050	11,283
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	600	590
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,025	8,455
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or	125	450



	small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	300	165
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,587	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	528	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,115	

### Implementing Mechanism Details

<b>Mechanism ID: 17376</b>	<b>Mechanism Name: Community HIV Link-Southern</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Promotion of Quality of Life	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	1
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	1
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17376		
<b>Mechanism Name:</b>	Community HIV Link-Southern		
<b>Prime Partner Name:</b>	Center for Promotion of Quality of Life		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	245,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	50,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	105,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,000	3,149
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	800	474
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	880	299
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	220	16
KP_PREV_DSD	By key population type: Men who have sex	2,100	2,200



	with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
--	--	--	--

### Implementing Mechanism Details

Mechanism ID: 17924	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 17925	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 17939	Mechanism Name: Evaluation, Monitoring and Survey Services
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Management Systems International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	250,000

### Sub Partner Name(s)



(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17939</b>			
<b>Mechanism Name: Evaluation, Monitoring and Survey Services</b>			
<b>Prime Partner Name: Management Systems International</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18149</b>	<b>Mechanism Name: CHP – HIV/AIDS Prevention</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Center for Community Health Promotion	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
-------------------------------------	--



<b>Applied Pipeline Amount: 597,800</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18149			
<b>Mechanism Name:</b> CHP – HIV/AIDS Prevention			
<b>Prime Partner Name:</b> Center for Community Health Promotion			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0



## Implementing Mechanism Indicator Information

(No data provided.)



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		154,000		154,000	0
ICASS		741,450		741,450	0
Non-ICASS Administrative Costs		446,692		446,692	0
Staff Program Travel		134,561		134,561	600,000
USG Staff Salaries and Benefits		1,602,990		1,602,990	0
<b>Total</b>	<b>0</b>	<b>3,079,693</b>	<b>0</b>	<b>3,079,693</b>	<b>600,000</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		0		0	40,000
ICASS		0		0	120,000
Management Meetings/Professional Development		0		0	75,000
Non-ICASS Administrative Costs		0		0	20,000



Staff Program Travel				0	80,000
USG Staff Salaries and Benefits		0		0	250,000
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>585,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		0		0	205,429
Computers/IT Services		0		0	133,035
ICASS		0		0	2,099,240
Institutional Contractors		0		0	1,107,590
Management Meetings/Professional Development		0		0	180,000
Non-ICASS Administrative Costs		0		0	312,000
Peace Corps Volunteer Costs				0	0
Staff Program Travel				0	380,000
USG Staff Salaries and Benefits	1,857,750			1,857,750	1,931,931
<b>Total</b>	<b>1,857,750</b>	<b>0</b>	<b>0</b>	<b>1,857,750</b>	<b>6,349,225</b>



**U.S. Department of Health and Human Services/Substance Abuse and Mental Health Services Administration**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		20,854		20,854	0
Computers/IT Services		15,000		15,000	0
ICASS		120,000		120,000	0
Management Meetings/Professional Development		10,000		10,000	0
Non-ICASS Administrative Costs		55,000		55,000	0
Staff Program Travel		171,479		171,479	0
USG Staff Salaries and Benefits		307,667		307,667	0
<b>Total</b>	<b>0</b>	<b>700,000</b>	<b>0</b>	<b>700,000</b>	<b>0</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		91,000		91,000	0
Non-ICASS Administrative Costs		0		0	50,000
Staff Program				0	35,000



Travel					
USG Staff Salaries and Benefits				0	77,000
<b>Total</b>	<b>0</b>	<b>91,000</b>	<b>0</b>	<b>91,000</b>	<b>162,000</b>